Please wait while we load the requested 10-K report or click the link below:
4Q19 total revenues of $1,384.3 million, a 23 percent increase over 4Q18
4Q19 GAAP diluted EPS of $4.00; non-GAAP diluted EPS of $2.71
Received Japanese approval for SOLIRIS® (eculizumab) for neuromyelitis optica spectrum disorder (NMOSD)
Established ULTOMIRIS® (ravulizumab) as market leader for PNH in U.S., Germany and Japan within first year of launch
Continued strong SOLIRIS gMG and NMOSD launches, making neurology largest franchise in U.S.
Expanded pipeline with 19 clinical-stage development programs planned for 2020 across 10 assets, including 2 Factor D inhibitors, following completion of Achillion acquisition
The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, January 30, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Alexion Pharmaceuticals, Inc..